Partner Nate Lacktman is quoted in a Fierce Healthcare article, “Does Healthcare Need a Virtual Medicine Specialty? Experts Aren’t So Sure,” about a proposal being floated by two physicians for a new medical specialty focusing primarily on virtual care.
Lacktman said the idea of a medical virtualist “betrays” the notion that virtual services should be viewed as another conduit to patient care. With telehealth still in the early stages of adoption – and health systems refining its use – he’d prefer that providers experiment with the technology before diving in to specialty care.
“It’s still early in the process,” he said. “Before we start laying the lines of what could be a turf war, let’s just use it and explore it.”
Lacktman said the idea of a medical virtualist “betrays” the notion that virtual services should be viewed as another conduit to patient care. With telehealth still in the early stages of adoption – and health systems refining its use – he’d prefer that providers experiment with the technology before diving in to specialty care.
“It’s still early in the process,” he said. “Before we start laying the lines of what could be a turf war, let’s just use it and explore it.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”